42265-79-2Relevant articles and documents
HIV REVERSE TRANSCRIPTASE INHIBITORS
-
Page/Page column 49, (2010/10/20)
Compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein T is O or S; U is O, S, N(R4), or a direct bond linking V to the C(=T) moiety; V is optionally substituted C1-6 alkylene; W is C(O)N(R5) or a direct bond linking V to R3; and R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Novel estrogen receptor ligands based on an anthranylaldoxime structure: Role of the phenol-type pseudocycle in the binding process
Minutolo, Filippo,Antonello, Michela,Bertini, Simone,Ortore, Gabriella,Placanica, Giorgio,Rapposelli, Simona,Sheng, Shubin,Carlson, Kathryn E.,Katzenellenbogen, Benita S.,Katzenellenbogen, John A.,Macchia, Marco
, p. 4032 - 4042 (2007/10/03)
The 3,4-diphenylsalicylaldoxime system 1 is an estrogen receptor (ER) ligand of unusual structure, having a hydrogen-bonded pseudocyclic A′-ring in place of the paradigmatic phenolic A-ring that is characteristic of most estrogens. We have investigated th
